At the news
? NEUTRALIMPACT 1/10 6-K filed Jul 13, 2026 at 11:28 ET
GSK filed a routine 6-K reporting PDMR share acquisitions under the company's Share Reward Plan and dividend reinvestment on July 9, 2026. Multiple executives including the CEO, CFO, and other senior leaders acquired small numbers of ordinary shares at ~£19.63, with the largest single purchase being 1,050 shares by a PCA of the Company Secretary. This is a standard administrative disclosure with no material financial or strategic implications.
- CEO Luke Miels acquired 3 ordinary shares via dividend reinvestment at £19.6290.
- CFO Julie Brown acquired 12 ordinary shares (6 partnership + 6 matching) under the Share Reward Plan at £19.6290.
- Largest single transaction: Iain Whyte (PCA of SVP & Company Secretary) acquired 1,050 shares via dividend reinvestment at £19.6297.
- All transactions occurred on July 9, 2026 on the London Stock Exchange.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access